| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 26 | — | 17.8x | Bottom tier | |
Growth | 55 | — | 7.1% | Around median | |
Quality | 19 | -10.9% | 4.5% | Bottom tier | |
Safety | 53 | — | 2.6x | Around median | |
Capital Return | 52 | — | 2.12% | Around median | |
Momentum | 10 | -39.6% | 2.9% | Bottom tier | |
Sentiment | 45 | 15 | 3 | Around median |
Estimates — analyst targets and a simplified DCF, not investment advice.
Oklo Inc. is developing an integrated nuclear platform spanning three interconnected businesses: energy, fuel, and radioisotopes. Aurora powerhouses are the core of the energy business and are designed to provide electricity and heat under long-term commercial arrangements, while the company works to build domestic capabilities for fuel supply, fabrication, and recycling. The isotope business targets healthcare, space, defense, industrial, and research markets, using a build-own-operate model to retain recurring revenue and operational expertise within the company.
In the second quarter of fiscal year 2026, Oklo recorded revenue of $1.2 million, the first quarterly revenue in its history, compared with no revenue in the second quarter of fiscal year 2025. However, the net loss widened to $48.5 million from $24.7 million, and loss per share was $0.28 versus $0.18; the available data did not include a gross profit or gross margin figure, so the economics of the initial revenue cannot yet be assessed.
For the first half of fiscal year 2026, the net loss was $81.6 million, including an operating loss of $124.2 million, partially offset by net interest and dividend income of $44.5 million. The company ended the second quarter of fiscal year 2026 with approximately $3 billion in cash and marketable securities, divided between $1.6 billion in cash and cash equivalents and $1.4 billion in securities, after raising $1.9 billion through at-the-market programs during fiscal year 2026.
Automated analysis for informational purposes only — not investment advice.
The analysts’ average price target is $84.57, within a wide range of $55 to $130, with a consensus rating of “Buy”; the average target remains far below the 52-week range peak of $193.84, reflecting a sharp revaluation relative to the year’s highest levels. No price-to-earnings ratio is available because losses continue, while the $7 billion market capitalization relative to quarterly revenue of $1.2 million places significant reliance on future execution, and the estimate reduction announced on August 10, 2026 adds meaningful weight to the conservative scenario despite the Buy consensus.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
Oklo recorded the first quarterly revenue in its history, totaling $1.2 million in the second quarter of fiscal year 2026, after recording no revenue in the comparable quarter of fiscal year 2025. Conversely, the net loss widened to $48.5 million from $24.7 million, and loss per share increased to $0.28 from $0.18. The results therefore mark the beginning of a commercial transition, but they do not yet establish profitability or margins, particularly because gross profit data were unavailable.
Groves reached initial criticality in early August 2026, just over 11 months after work began at the site, with substantial construction work completed within 229 days. Oklo built the facility on private land with private financing and handled design, procurement, construction, and operations, while the Department of Energy provided the oversight and safety pathway. This gives the company trained teams, supplier data, and operating and licensing procedures that can be transferred to subsequent projects, but it does not eliminate the differing requirements of Aurora and fuel facilities.
Management said on the August 7, 2026 call that the first revenue from the isotope business will most likely come from the NRC-licensed Idaho laboratory during the first part of 2027. The laboratory is conducting commercial discussions with several companies regarding potential offtake agreements and can also process, recover, and purify isotopes from existing inventories. As for Groves, the company expects it to begin producing research and development quantities within approximately 12 months of the call, alongside planning for a subsequent isotope facility for larger-scale production.
Oklo ended the second quarter of fiscal year 2026 with approximately $3 billion in cash and marketable securities, including $1.6 billion in cash and cash equivalents and $1.4 billion in securities. The balance included $1.9 billion raised through at-the-market programs during fiscal year 2026. Management says this liquidity covers the fiscal year 2026 plan, but the company raised its operating cash usage range to $120–150 million and its property, plant, and equipment spending range to $400–500 million as Aurora INL work accelerates.
Oklo uses a multi-pathway strategy that includes recovered EBR-II fuel, commercial HALEU, potential government plutonium, and recycling. The letter of intent with Centrus, following the execution of a definitive agreement, is expected to provide initial core loads and reloads for up to five Aurora powerhouses for several years, with deliveries expected to begin in 2029. Equipment for the A3F facility is also now in production for installation and the start of activities in 2027, while plutonium allocations remain subject to a Department of Energy decision, agreement, and safeguards.
Oklo plans a 1.2-gigawatt clean energy campus in Ohio to supply power to Meta and signed a memorandum of understanding with Kiewit in the second quarter of fiscal year 2026 to plan the engineering, procurement, and construction of the first phase. The company is advancing more than one request through the PJM interconnection process, but management described the time required to complete interconnection procedures as an important watchpoint. Execution also depends on replicating the Aurora model across multiple powerhouses and securing fuel, financing, and construction within schedules whose full costs have not yet been determined.
